This is the hottest job in Houston for college grads, says new study

help wanted

Petroleum engineers do well in Houston. Photo courtesy of Society for Petroleum Engineers

Are you a newly minted college grad searching for an in-demand job in Houston? If you're a petroleum engineer, you're in luck.

A study published May 27 by RentCafé, a platform for apartment rentals, shows the hottest job in Houston for college grads is petroleum engineer. RentCafé based its list of hot jobs on two factors: median pay and jobs per 1,000. The median pay for petroleum engineers in Houston is $178,240 and the rage of jobs per 1,000 is a mere 2.77

Austin? If you're a software developer, you're in luck.

As identified by RentCafé, here are the five hottest jobs in Houston for college grads:

  1. Petroleum engineer
  2. Sales manager
  3. Computer systems analyst
  4. Geoscientist
  5. Medical and health services manager

What follows are the hottest jobs for college grads in Texas' other major metro areas.

Austin
  1. Software developer / software quality assurance analyst and tester
  2. College education administrator
  3. Database administrator and architect
  4. Information security analyst
  5. Administrative services and facilities manager

Dallas-Fort Worth

  1. Sales manager
  2. Software developer / software quality assurance analyst and tester
  3. Information security analyst
  4. Medical and health services manager
  5. Computer systems analyst

San Antonio

  1. Medical and health services manager
  2. Software developer / software quality assurance analyst and tester
  3. Sales manager
  4. Computer systems analyst
  5. Nurse practitioner
------

This article originally ran on CultureMap.

The median income in Houston grew more than 20 percent from 2010 to 2019. Photo by DenisTangneyJr/Getty Images

Here's how much Houston's household income grew over past decade

Money matters

Houston's household income jumped in the 2010s, but not as significantly as many other major U.S. metros, a new report shows.

Data compiled by apartment website RentCafé and published December 16 shows median household income inside the city of Houston (not the metro area) jumped 23.9 percent during the decade.

Houston ranks No. 40 for the rise in household income among the country's 50 largest cities. Houston's median household income grew from $42,355 in 2010 to $52,483 in 2019, according to RentCafé. For 2010 income, the website pulled data from the U.S. Census Bureau; it estimated 2019 household income based on a predicted 2.5 percent increase in the U.S. Consumer Price Index.

By comparison, the U.S. median household income stood at $63,179 in 2018, according to the Census Bureau, and Texas median household income checked in at $60,629.

"We're better off by almost all measures than we were 10 years ago," Carl Tannenbaum, chief economist for Northern Trust, told the Wall Street Journal in September. "But there are still some … flags that show that economic security remains more elusive for some families."

Only one Texas city ranked among the country's top 10. Austin, No. 8, saw a 54.6 percent hike during the decade, from $47,434 in 2010 to $73,332 in 2019.

As ranked by RentCafé, the top 10 cities for growth in median household income from 2010 to 2019 are:

  1. Atlanta, 60.9 percent
  2. San Francisco, 60.5 percent
  3. Oakland, California, 59.3 percent
  4. Seattle, 59.1 percent
  5. Portland, Oregon, 58.8 percent
  6. Miami, 57.1 percent
  7. Denver, 55.5 percent
  8. Austin, 54.6 percent
  9. San Jose, California, 50.9 percent
  10. Brooklyn, New York, 48.9 percent

Well down the ladder is Dallas, at No. 27. From 2010 to 2019, the city's median household income surged 31.6 percent — from $40,650 to $53,515.

At No. 38 is Fort Worth, where median household income increased 24.2 percent during the 10-year span — from $48,224 to $59,909.

San Antonio hovers close to the bottom of the 50-city list. Alamo City ranked 46th, with a 14.8 percent gain over the 10-year period. Median household income went from $43,758 to $50,250.

------

This article originally ran on CultureMap.

Houston will end this decade with 114,100 new apartments having been built in the last 10 years. Photo courtesy of Dolce Midtown Apartments

Houston area sees more new apartments than almost any other city

built up

You might call this the Decade of the Renter in Houston. New data shows H-Town ranks third in the U.S. for most new apartments from 2010 through 2019.

In a housing review of the 2010s published December 16, apartment website RentCafé estimates Houston will end this decade with 114,100 new apartments having been built during the 10-year span.

Houston is eclipsed by only two markets: DFW, with an estimated 149,000 new apartments, and New York City, with an estimated 125,100 new apartments added during this decade. In the rankings, Houston is followed by Washington, D.C. (113,300) and Los Angeles (98,000).

Two other Texas metros made the top 20:

  • Austin, claiming the No. 8 spot with 75,400 new apartments.
  • San Antonio, grabbing the No. 13 spot with 47,700 new apartments.

All told, the four major metro areas in Texas have added 386,200 new apartments from 2010 through 2019, RentCafé data shows. At the same time, their populations have exploded.

From April 2010 to July 2018, the DFW metro area's population soared by more than 1.1 million, according to the U.S. Census Bureau. Houston nipped on DFW's heels from 2010 to 2018, adding almost 1.08 million residents, the Census Bureau says.

During the same period, comparatively rapid growth occurred in the Austin metro area (nearly 452,000 new residents) and San Antonio metro area (more than 375,000 new residents).

As Texas' major metro areas keep experiencing a population surge, the rise of the apartment renter promises to continue.

Data from Richardson-based property management software RealPage shows construction of 22,879 new apartments had been approved from October 2018 to October 2019 in the Houston area. That's a year-over-year jump of 77.8 percent.

The numbers for DFW (19,562 permits, up 7.3 percent) and Austin (13,981, up 15 percent) were lower, but they still ranked among RealPage's top 10 metro markets for the number of apartment construction permits issued.

Within U.S. metro areas, the cities of Houston, Austin, and San Antonio ranked among the top 10 places for apartment construction permits issued from October 2018 to October 2019, according to RealPage.

------

This article originally ran on CultureMap.

Dolce Midtown Apartments is one of the many new apartment options in the Houston area. Photo courtesy of Dolce Midtown Apartments

Houston booms among nation's top 10 markets for new apartments

They come, we build

It's not all in your head. Those new apartments you spotted on your way to work probably did just pop up — and it's happening in big numbers in Houston and around the state, according to a new study.

RentCafe estimates 7,143 new apartments will be built in the Houston metro by the end of 2019 — the 10th highest projection nationally. Nearly half of those new units will rise within the city of Houston proper.

And these aren't vanity projects. With more than 90,000 new residents calling the Houston area home, we need all the apartments we can get.

Houston leads the region in terms of projected new apartment units at 3,163, followed by Conroe's 724 expected units and The Woodlands' 678.

Most of Texas is booming, too. No. 1 on RentCafe's list is Dallas-Fort Worth, with 22,196 new units expected by the end of the year. No. 5 Austin is expected to bring 10,783 new units to the region. Meanwhile, 3,510 new units will be built in San Antonio, a steep decline of 41 percent from the 5,993 units built there in 2018.

Nationally, Seattle makes for a distant second behind DFW with 13,682 new units expected, followed by New York City, which was No. 1 in 2018, with 13,418 units planned for this year.

Unlike the Lone Star State, the nation as a whole is seeing a slump in apartment construction. The 299,442 new apartments expected in 2019 represent an 8.2 percent drop from 2018's 326,240 new units, which also were weaker numbers than in 2017, when 331,765 new apartments were built.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings